{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-025179","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.470227+00:00","generated_at":"2026-05-31T11:38:19.121041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omeros Q2 net loss $56M ($0.97/sh) vs $37M; restructures debt with $67M term loan","bullets":["Net loss $56.0M ($0.97/sh) vs $37.3M ($0.59); includes $17.6M narsoplimab charge, $21.2M debt repurchase.","Entered $67.1M secured term loan with Athyrium/Highbridge; repurchased $118.1M of 5.25% 2026 notes at ~25% discount.","Cash and investments $158.9M at June 30; OMIDRIA royalties $10.9M on Rayner net sales $36.4M.","FDA meeting scheduled for narsoplimab BLA resubmission in TA-TMA; Phase 3 for zaltenibart in PNH on track for late 2024.","Zaltenibart Phase 2 data: mean hemoglobin improvement 3.27 g/dL; 10/12 patients advanced to monotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-025179","json":"https://secwatch.observer/filing/0001437749-24-025179.json","markdown":"https://secwatch.observer/filing/0001437749-24-025179.md","text":"https://secwatch.observer/filing/0001437749-24-025179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924025179/0001437749-24-025179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924025179/omer20240523_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:38:19.121041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}